Temporal changes in childhood cancer incidence and survival by stage at diagnosis in Australia, 2000–2017

References

• Gupta S, Aitken JF, Bartels U, et al. Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. Lancet Oncol. 2016;17(4):e163-172–e172. doi: 10.1016/S1470-2045(15)00539-2.
   Web of Science ®Google Scholar
• Piñeros M, Parkin DM, Ward K, et al. Essential TNM: a registry tool to reduce gaps in cancer staging information. Lancet Oncol. 2019;20(2):e103–e111. doi: 10.1016/S1470-2045(18)30897-0.
   PubMed Web of Science ®Google Scholar
• Walters S, Maringe C, Butler J, et al. Comparability of stage data in cancer registries in six countries: lessons from the international cancer benchmarking partnership. Int J Cancer. 2013;132(3):676–685. doi: 10.1002/ijc.27651.
   PubMed Web of Science ®Google Scholar
• Fritz A, Percy C, Jack A, et al. editors. International classification of diseases for oncology (ICD-O). Third edition. Geneva, Switzerland: WHO; 2000.
   Google Scholar
• Brierley J, Gospodarowicz M, Wittekind C, editors. The TNM classification of malignant tumours., 8th edition. Hoboken, NJ: John Wiley and Sons Inc; 2017.
   Google Scholar
• Steliarova-Foucher E, Stiller C, Lacour B, et al. International classification of childhood cancer, third edition. Cancer. 2005;103(7):1457–1467. doi: 10.1002/cncr.20910.
   PubMed Web of Science ®Google Scholar
• Gupta S, Aitken J, Bartels U, et al. Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto paediatric cancer stage guidelines. Lancet Oncol. 2020;21(9):e444–e451. doi: 10.1016/S1470-2045(20)30320-X.
   PubMed Web of Science ®Google Scholar
• Youlden DR, Baade PD, Moore AS, et al. Childhood cancer survival and avoided deaths in Australia, 1983–2016. Paediatr Perinat Epidemiol. 2023;37(1):81–91. doi: 10.1111/ppe.12895.
   PubMed Web of Science ®Google Scholar
• Schindler M, Belle FN, Grotzer MA, et al. Childhood cancer survival in Switzerland (1976-2013): time-trends and predictors. Int J Cancer. 2017;140(1):62–74. doi: 10.1002/ijc.30434.
   PubMed Web of Science ®Google Scholar
• Siegel DA, Richardson LC, Henley SJ, et al. Pediatric cancer mortality and survival in the United States, 2001–2016. Cancer. 2020;126(19):4379–4389. doi: 10.1002/cncr.33080.
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. National Death Index (NDI) Canberra: AIHW; 2022. Available from: https://www.aihw.gov.au/about-our-data/our-data-collections/national-death-index. Accessed 30 November 2022.
   Google Scholar
• Aitken JF, Youlden DR, Moore AS, et al. Assessing the feasibility and validity of the toronto childhood cancer stage guidelines: a population-based registry study. Lancet Child Adolesc Health. 2018;2(3):173–179. doi: 10.1016/S2352-4642(18)30023-3.
   PubMedGoogle Scholar
• Winick N, Devidas M, Chen S, et al. Impact of initial CSF findings on outcome among patients with national cancer institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol. 2017;35(22):2527–2534. doi: 10.1200/JCO.2016.71.4774.
   PubMed Web of Science ®Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1861.
   PubMed Web of Science ®Google Scholar
• Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–339.
   PubMed Web of Science ®Google Scholar
• Harisiadis L, Chang CH. Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys. 1977;2(9-10):833–841. doi: 10.1016/0360-3016(77)90181-x.
   PubMed Web of Science ®Google Scholar
• Monclair T, Brodeur GM, Ambros PF, et al. The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol. 2009;27(2):298–303. doi: 10.1200/JCO.2008.16.6876.
   PubMed Web of Science ®Google Scholar
• Chantada G, Doz F, Antoneli CBG, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47(6):801–805. doi: 10.1002/pbc.20606.
   PubMed Web of Science ®Google Scholar
• Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. doi: 10.1016/j.ijgo.2013.10.001.
   PubMed Web of Science ®Google Scholar
• Iinternational Association of Cancer Registries. 2022. Paediatric Cancer Stage Guidelines. [cited 2022 Nov 28] Available from: http://www.iacr.com.fr/index.php?option=com_content&view=article&id=153&Itemid=657.
   Google Scholar
• Swaminathan R, Brenner H. Statistical methods for cancer survival analysis. In: sankaranarayanan R, Swaminathan RL, E, editors. Cancer survival in africa, asia, the caribbean and Central America (IARC scientific publication no. 162. Lyon: IARC; 2011. p. 7–13.
   Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata. 2009;9(2):265–290. doi: 10.1177/1536867X0900900206.
   Web of Science ®Google Scholar
• Mendoza PR, Grossniklaus HE. Therapeutic options for retinoblastoma. Cancer Control. 2016;23(2):99–109. doi: 10.1177/107327481602300203.
   PubMed Web of Science ®Google Scholar
• Brennan RC, Qaddoumi I, Mao S, et al. Ocular salvage and vision preservation using a Topotecan-Based regimen for advanced intraocular retinoblastoma. J Clin Oncol. 2017;35(1):72–77. doi: 10.1200/JCO.2016.69.2996.
   PubMed Web of Science ®Google Scholar
• Rajeshuni N, Whittemore AS, Ludwig CA, et al. Racial, ethnic, and socioeconomic disparities in retinoblastoma enucleation: a population-based study, SEER 18 2000-2014. Am J Ophthalmol. 2019;207:215–223. doi: 10.1016/j.ajo.2019.04.015.
   PubMed Web of Science ®Google Scholar
• Posner M, Jaulim A, Vasalaki M, et al. Lag time for retinoblastoma in the UK revisited: a retrospective analysis. BMJ Open. 2017;7(7):e015625. doi: 10.1136/bmjopen-2016-015625.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou C, He F, et al. Contemporary update of retinoblastoma in China: three-Decade changes in epidemiology, clinical features, treatments, and outcomes. Am J Ophthalmol. 2022;236:193–203. doi: 10.1016/j.ajo.2021.09.026.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Youlden DR, Chitsike I, et al. Stage at diagnosis and survival by stage for the leading childhood cancers in three populations of sub-Saharan Africa. Int J Cancer. 2021;148(11):2685–2691. doi: 10.1002/ijc.33468.
   PubMed Web of Science ®Google Scholar
• Fabian ID, Abdallah E, Abdullahi SU, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020;6(5):685–695. doi: 10.1001/jamaoncol.2019.6716.
   PubMed Web of Science ®Google Scholar
• McCarville MB, Roebuck DJ. Diagnosis and staging of hepatoblastoma: imaging aspects. Pediatr Blood Cancer. 2012;59(5):793–799. doi: 10.1002/pbc.24221.
   PubMed Web of Science ®Google Scholar
• Angelico R, Grimaldi C, Gazia C, et al. How do synchronous lung metastases influence the surgical management of children with hepatoblastoma? An update and systematic review of the literature. Cancers (Basel). 2019;11(11):1693. doi: 10.3390/cancers11111693.
   PubMed Web of Science ®Google Scholar
• Berthold F, Spix C, Kaatsch P, et al. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979–2015. Paediatr Drugs. 2017;19(6):577–593. doi: 10.1007/s40272-017-0251-3.
   PubMed Web of Science ®Google Scholar
• Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the children’s oncology group. J Clin Oncol. 2021;39(29):3229–3241. doi: 10.1200/JCO.21.00278.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334. doi: 10.1056/NEJMoa0911123.
   PubMed Web of Science ®Google Scholar
• Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on Event-Free survival in patients with High-Risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746–755. doi: 10.1001/jama.2019.11642.
   PubMed Web of Science ®Google Scholar
• Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008;41(2):159–165. doi: 10.1038/sj.bmt.1705929.
   PubMed Web of Science ®Google Scholar
• Punyko JA, Mertens AC, Baker KS, et al. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer. 2005;103(7):1475–1483. doi: 10.1002/cncr.20929.
   PubMed Web of Science ®Google Scholar
• Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(11):1566–1575. doi: 10.1016/S1470-2045(19)30617-5.
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Lyden E, Anderson JR, et al. Intensive multiagent therapy, including Dose-Compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/ cyclophosphamide, irinotecan, and radiation, in patients with High-Risk rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol. 2016;34(2):117–122. doi: 10.1200/JCO.2015.63.4048.
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26(14):2384–2389. doi: 10.1200/JCO.2007.14.7207.
   PubMed Web of Science ®Google Scholar
• Johnston DL, Keene D, Kostova M, et al. Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. J Neurooncol. 2015;124(2):247–253. doi: 10.1007/s11060-015-1831-0.
   PubMed Web of Science ®Google Scholar
• Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013;31(23):2936–2941. doi: 10.1200/JCO.2012.43.9984.
   PubMed Web of Science ®Google Scholar
• Leary SES, Packer RJ, Li Y, et al. Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the children’s oncology group. JAMA Oncol. 2021;7(9):1313–1321. doi: 10.1001/jamaoncol.2021.2224.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St jude medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813–820. doi: 10.1016/S1470-2045(06)70867-1.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with Risk-Adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncol. 2021;39(7):822–835. doi: 10.1200/JCO.20.01372.
   PubMed Web of Science ®Google Scholar
• Botta L, Gatta G, Didonè F, et al. International benchmarking of childhood cancer survival by stage at diagnosis: the BENCHISTA project protocol. PLoS One. 2022;17(11):e0276997. doi: 10.1371/journal.pone.0276997.
   PubMed Web of Science ®Google Scholar